Ignite Creation Date:
2025-12-24 @ 11:39 PM
Ignite Modification Date:
2026-02-23 @ 4:55 AM
Study NCT ID:
NCT02621151
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-07
First Post:
2015-12-01
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
Sponsor:
NYU Langone Health
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-08-11
Start Date Type:
ACTUAL
Primary Completion Date:
2022-11-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-12
Completion Date Type:
ESTIMATED
First Submit Date:
2015-12-01
First Submit QC Date:
None
Study First Post Date:
2015-12-03
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2025-07-21
Results First Submit QC Date:
None
Results First Post Date:
2025-10-07
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-17
Last Update Post Date:
2025-10-07
Last Update Post Date Type:
ESTIMATED